RMD Stock Analysis: ResMed | NYSE
Medical Instruments & Supplies | NYSE, USA | Market Cap: 33.097m USD | 12M Return: -5.4% | US7611521078 | Charts, Fundamentals & Technical Analysis
Avg Turnover: 335M
EPS Trend: 99.2%
Qual. Beats: 2
Rev. Trend: 99.9%
Qual. Beats: 1
Warnings
Tailwinds
No distinct edge detected
Seasonality 11.9 years of data, until 10/2026
How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, ≥40 worth a closer look and ≥60 is strong.
ResMed Inc. (NYSE: RMD) is a U.S.-based digital health and medical device company operating in two main segments: Sleep and Breathing Health, and Residential Care Software. The company manufactures diagnostic tools for sleep apnea, including portable recorders like ApneaLink Air and the cloud-connected NightOwl device, and provides connected therapy solutions such as AirView for remote monitoring and the myAir patient engagement app. Through its Residential Care Software segment, ResMed offers SaaS-based platforms-including Brightree, HEALTHCAREfirst, MatrixCare, and MEDIFOX DAN-serving home medical equipment, home health, hospice, skilled nursing, and senior living providers.
Founded in 1989 and headquartered in San Diego, California, ResMed is classified as a large-cap stock in the Health Care Equipment sub-industry, with operations spanning the U.S. and international markets. The company sits at the intersection of medical device manufacturing and healthcare software, leveraging connectivity and cloud platforms to support chronic disease management, particularly sleep-disordered breathing and post-acute care.
- GLP-1 weight loss drugs threaten sleep apnea device demand
- Philips recall recovery intensifies competition in CPAP market
- Residential Care Software segment drives recurring revenue growth
| Net Income: 1.59b TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.35 > 0.02 and ΔFCF/TA 13.42 > 1.0 |
| NWC/Revenue: 38.11% < 20% (prev 45.08%; Δ -6.97% < -1%) |
| CFO/TA 0.38 > 3% & CFO 3.12b > Net Income 1.59b |
| Net Debt (-199.2m) to EBITDA (2.24b): -0.09 < 3 |
| Current Ratio: 2.65 > 1.5 & < 3 |
| Outstanding Shares: last quarter (143.4m) vs 12m ago -2.47% < -2% |
| Gross Margin: 61.18% > 18% (prev 60.08%; Δ 1.10% > 0.5%) |
| Asset Turnover: 69.40% > 50% (prev 63.28%; Δ 6.12% > 0%) |
| Interest Coverage Ratio: 43.79 > 6 (EBIT TTM 2.01b / Interest Expense TTM 45.9m) |
| A: 0.27 (Total Current Assets 3.51b - Total Current Liabilities 1.32b) / Total Assets 8.21b |
| B: 0.92 (Retained Earnings 7.58b / Total Assets 8.21b) |
| C: 0.24 (EBIT TTM 2.01b / Avg Total Assets 8.26b) |
| D: 2.63 (Book Value of Equity 5.95b / Total Liabilities 2.26b) |
| Altman-Z'' = 9.15 = AAA |
| DSRI: 0.93 (Receivables 972.5m/958.4m, Revenue 5.73b/5.26b) |
| GMI: 0.98 (GM 60.08% / 61.18%) |
| AQI: 1.00 (AQ_t 0.48 / AQ_t-1 0.48) |
| SGI: 1.09 (Revenue 5.73b / 5.26b) |
| TATA: -0.19 (NI 1.59b - CFO 3.12b) / TA 8.21b) |
| Beneish M = -3.06 (Cap -4..+1) = AA |
As of November 11, 2026, the stock is trading at USD 234.11 with a total of 1,157,918 shares traded. Over the past week, the price has changed by +3.10%, over one month by -0.21%, over three months by +6.69% and over the past year by -5.40%.
Current recommended Stop Loss: 224.40 (which is 4.1% or 1.2 ATR below the current price).
ResMed has received a consensus analysts rating of 3.70. Therefore, it is recommended to hold RMD.
- StrongBuy: 7
- Buy: 2
- Hold: 10
- Sell: 0
- StrongSell: 1
| Analysts Target Price | 264.3 | 12.9% |
P/E Trailing = 21.4299
P/E Forward = 19.6078
P/S = 5.7733
P/B = 5.5646
P/EG = 1.2599
Revenue TTM = 5.73b USD
EBIT TTM = 2.01b USD
EBITDA TTM = 2.24b USD
Long Term Debt = 249.6m USD (from longTermDebt, last quarter)
Short Term Debt = 191.5m USD (from shortTermDebt, last quarter)
Debt = 811.6m USD (from shortLongTermDebtTotal, last quarter) + Leases 201.0m
Net Debt = -199.2m USD (calculated: Debt 811.6m - CCE 1.01b)
Enterprise Value = 32.9b USD (33.1b + Debt 811.6m - CCE 1.01b)
Interest Coverage Ratio = 43.79 (Ebit TTM 2.01b / Interest Expense TTM 45.9m)
EV/FCF = 11.55x (Enterprise Value 32.9b / FCF TTM 2.85b)
FCF Yield = 8.66% (FCF TTM 2.85b / Enterprise Value 32.9b)
FCF Margin = 49.70% (FCF TTM 2.85b / Revenue TTM 5.73b)
Net Margin = 27.79% (Net Income TTM 1.59b / Revenue TTM 5.73b)
Gross Margin = 61.18% ((Revenue TTM 5.73b - Cost of Revenue TTM 2.23b) / Revenue TTM)
Gross Margin QoQ = 61.53% (prev 58.84%)
Tobins Q-Ratio = 4.01 (Enterprise Value 32.9b / Total Assets 8.21b)
Interest Expense / Debt = 5.66% (Interest Expense 45.9m / Debt 811.6m)
Taxrate = 20.81% (418.6m / 2.01b)
NOPAT = 1.59b (EBIT 2.01b * (1 - 20.81%))
Current Ratio = 2.65 (Total Current Assets 3.51b / Total Current Liabilities 1.32b)
Debt / Equity = 0.14 (Debt 811.6m / totalStockholderEquity, last quarter 5.95b)
Debt / EBITDA = -0.09 (Net Debt -199.2m / EBITDA 2.24b)
Debt / FCF = -0.07 (Net Debt -199.2m / FCF TTM 2.85b)
Total Stockholder Equity = 6.34b (last 4 quarters mean from totalStockholderEquity)
RoA = 19.29% (Net Income 1.59b / Total Assets 8.21b)
RoE = 25.14% (Net Income TTM 1.59b / Total Stockholder Equity 6.34b)
RoCE = 30.54% (EBIT 2.01b / Capital Employed (Equity 6.34b + L.T.Debt 249.6m))
RoIC = 23.45% (NOPAT 1.59b / Invested Capital 6.79b)
WACC = 7.05% (E(33.1b)/V(33.9b) * Re(7.11%) + D(811.6m)/V(33.9b) * Rd(5.66%) * (1-Tc(0.21)))
Discount Rate = 7.11% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: -79.00 | Cagr: -1.25%
[DCF] Terminal Value 77.97% ; FCFF base≈2.42b ; Y1≈2.77b ; Y5≈4.08b
[DCF] Fair Price = 437.5 (EV 61.3b - Net Debt -199.2m = Equity 61.5b / Shares 140.7m; r=8.35% [WACC [floored]]; 5y FCF grow 15.0% → 2.50% )
EPS Correlation: 99.20 | EPS CAGR: 20.76% | SUE: 4.0 | # QB: 2
Revenue Correlation: 99.93 | Revenue CAGR: 9.53% | SUE: 1.62 | # QB: 1
EPS current Quarter (2026-12-31): EPS=2.99 | Chg30d=-1.37% | Revisions=-50% | Analysts=13
EPS next Quarter (2027-03-31): EPS=3.06 | Chg30d=-2.86% | Revisions=-70% | Analysts=13
EPS current Year (2027-06-30): EPS=12.14 | Chg30d=+0.46% | Revisions=+15% | GrowthEPS=+8.7% | GrowthRev=+3.1%
EPS next Year (2028-06-30): EPS=13.23 | Chg30d=-0.03% | Revisions=-8% | GrowthEPS=+8.9% | GrowthRev=+6.4%
[Analyst] Revisions Ratio: -31% (up=11, down=22)